Literature DB >> 2866266

Venodilating action of nipradilol (K-351) in the pithed rat pretreated with dihydroergotamine.

Y Shirasawa, M Fujii, M Nakamura.   

Abstract

The venodilating action of nipradilol was investigated by monitoring arterial blood pressure (BP), cardiac output (CO), heart rate (HR) and central venous pressure (CVP) in pithed rats treated with dihydroergotamine (DHE). DHE increased CVP and produced a simultaneous rise in BP and CO without appreciable changes in total peripheral resistance (TPR) and HR, indicating that DHE reduces venous capacity through venoconstriction. Nipradilol caused a fall in CVP, BP and CO without changing the TPR in the DHE-pretreated rat. By comparison, hydralazine reduced BP and TPR without changes in CO. Propranolol produced only a transient decrease in BP and TPR. These results indicate that nipradilol dilates venous capacitance vessels and thereby decreases cardiac filling pressure in animals with high venous tone, whereas hydralazine preferentially dilates resistance vessels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866266     DOI: 10.1254/jjp.39.77

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  5 in total

Review 1.  The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

2.  Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans.

Authors:  M Kanno; M Araie; H Koibuchi; K Masuda
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

3.  Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study.

Authors:  Makoto Araie; Shiroaki Shirato; Yoshio Yamazaki; Yoshiaki Kitazawa; Yasuo Ohashi
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

4.  Nipradilol, a new beta-adrenergic blocker, reduces left ventricular remodeling following myocardial infarction in spontaneously hypertensive rats.

Authors:  H Sonoki; M Nakamura; A Takeshita
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

5.  Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes.

Authors:  Mitsushi Fukukita; Masashi Ido; Syunsuke Osawa; Mikio Sasoh; Motoyasu Furuta; Kunio Ito; Masahiko Sugimoto; Yukitaka Uji
Journal:  J Ophthalmol       Date:  2011-11-03       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.